Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Eur Radiol

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    February 2024
  1. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    PubMed     Abstract available


    January 2024
  2. MAZZETTI S, Defeudis A, Nicoletti G, Chiorino G, et al
    Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
    Eur Radiol. 2024 Jan 4. doi: 10.1007/s00330-023-10542.
    PubMed     Abstract available


  3. PANEBIANCO V
    Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10547.
    PubMed    


    December 2023
  4. EVANGELISTA L, Filippi L
    Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.
    Eur Radiol. 2023 Dec 20. doi: 10.1007/s00330-023-10507.
    PubMed    


  5. NOTO B, Eveslage M, Auf der Springe K, Exler A, et al
    Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.
    Eur Radiol. 2023 Dec 15. doi: 10.1007/s00330-023-10406.
    PubMed     Abstract available


  6. JANNUSCH K, Bruckmann NM, Morawitz J, Boschheidgen M, et al
    Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI.
    Eur Radiol. 2023 Dec 1. doi: 10.1007/s00330-023-10442.
    PubMed     Abstract available


  7. ROUVIERE O
    Contrast-medium administration for prostate MRI can be abandoned: no(t so simple)!
    Eur Radiol. 2023;33:8415-8416.
    PubMed    


  8. ASBACH P
    Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned.
    Eur Radiol. 2023;33:8413-8414.
    PubMed    


    November 2023
  9. MA J, Yang Q, Ye X, Xu W, et al
    Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.
    Eur Radiol. 2023 Nov 20. doi: 10.1007/s00330-023-10436.
    PubMed     Abstract available


  10. NETZER N, Eith C, Bethge O, Hielscher T, et al
    Application of a validated prostate MRI deep learning system to independent same-vendor multi-institutional data: demonstration of transferability.
    Eur Radiol. 2023;33:7463-7476.
    PubMed     Abstract available


    September 2023
  11. COHEN D, Hazut Krauthammer S, Fahoum I, Kesler M, et al
    PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.
    Eur Radiol. 2023;33:6502-6512.
    PubMed     Abstract available


    August 2023
  12. FRANCO PN, Frade-Santos S, Garcia-Baizan A, Paredes-Velazquez L, et al
    An MRI assessment of prostate cancer local recurrence using the PI-RR system: diagnostic accuracy, inter-observer reliability among readers with variable experience, and correlation with PSA values.
    Eur Radiol. 2023 Aug 30. doi: 10.1007/s00330-023-09949.
    PubMed     Abstract available


  13. GRAWE F, Blom F, Winkelmann M, Burgard C, et al
    Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
    Eur Radiol. 2023 Aug 25. doi: 10.1007/s00330-023-10083.
    PubMed     Abstract available


  14. DONNERS R, Tunariu N, Tovey H, Hall E, et al
    The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Eur Radiol. 2023 Aug 24. doi: 10.1007/s00330-023-10172.
    PubMed     Abstract available


  15. MESSINA E, La Torre G, Pecoraro M, Pisciotti ML, et al
    Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
    Eur Radiol. 2023 Aug 10. doi: 10.1007/s00330-023-10019.
    PubMed     Abstract available


  16. MESSINA E, Pecoraro M, Laschena L, Bicchetti M, et al
    Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Eur Radiol. 2023;33:5828-5839.
    PubMed     Abstract available


    July 2023
  17. NHAT TO MN, Kwak JT
    Retraction Note: Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2023 Jul 31. doi: 10.1007/s00330-023-09887.
    PubMed    


  18. LIU G, Pan S, Zhao R, Zhou H, et al
    The added value of AI-based computer-aided diagnosis in classification of cancer at prostate MRI.
    Eur Radiol. 2023;33:5118-5130.
    PubMed     Abstract available


  19. JIMENEZ-PASTOR A, Lopez-Gonzalez R, Fos-Guarinos B, Garcia-Castro F, et al
    Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks.
    Eur Radiol. 2023;33:5087-5096.
    PubMed     Abstract available


    May 2023
  20. ASBACH P, Padhani AR
    Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09711.
    PubMed    


  21. PADHANI AR, Schoots IG
    Prostate cancer screening-stepping forward with MRI.
    Eur Radiol. 2023 May 8. doi: 10.1007/s00330-023-09673.
    PubMed     Abstract available


  22. PUECH P, Gutierrez PA, Berg-Logager V, Villeirs G, et al
    How should we prepare a generation of radiologists for MRI-based prostate cancer screening?
    Eur Radiol. 2023 May 6. doi: 10.1007/s00330-023-09680.
    PubMed    


  23. DONSWIJK ML, Piek MW, Cheung Z, Wondergem M, et al
    Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer.
    Eur Radiol. 2023;33:3377-3385.
    PubMed     Abstract available


  24. VEERMAN H, Hagens MJ, Hoeks CM, van der Poel HG, et al
    A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement.
    Eur Radiol. 2023;33:3295-3302.
    PubMed     Abstract available


    April 2023
  25. MARTURANO F, Guglielmo P, Bettinelli A, Zattoni F, et al
    Role of radiomic analysis of [(18)F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging.
    Eur Radiol. 2023 Apr 20. doi: 10.1007/s00330-023-09642.
    PubMed     Abstract available


  26. GAUR S
    Commentary: considering radiomics in the setting of prostate cancer active surveillance.
    Eur Radiol. 2023 Apr 18. doi: 10.1007/s00330-023-09634.
    PubMed    


  27. SCHIRO S, Milanese G, Maddalo M, Ziglioli F, et al
    MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models.
    Eur Radiol. 2023;33:2975-2984.
    PubMed     Abstract available


  28. THIMANSSON E, Bengtsson J, Baubeta E, Engman J, et al
    Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI.
    Eur Radiol. 2023;33:2519-2528.
    PubMed     Abstract available


  29. PARK MY, Park KJ, Kim MH, Kim JK, et al
    Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value.
    Eur Radiol. 2023;33:2985-2994.
    PubMed     Abstract available


    March 2023
  30. QIN C, Goldberg O, Kakar G, Wan S, et al
    MRI fat fraction imaging of nodal and bone metastases in prostate cancer.
    Eur Radiol. 2023 Mar 16. doi: 10.1007/s00330-023-09527.
    PubMed     Abstract available


  31. BAUCKNEHT M, Miceli A, Signori A, Albano D, et al
    Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
    Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
    PubMed     Abstract available


    February 2023
  32. SUSHENTSEV N, Rundo L, Abrego L, Li Z, et al
    Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2023 Feb 7. doi: 10.1007/s00330-023-09438.
    PubMed     Abstract available


    January 2023
  33. LABUS S, Altmann MM, Huisman H, Tong A, et al
    A concurrent, deep learning-based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists.
    Eur Radiol. 2023;33:64-76.
    PubMed     Abstract available


  34. GIGANTI F, Cole AP, Fennessy FM, Clinton T, et al
    Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
    Eur Radiol. 2023;33:461-471.
    PubMed     Abstract available


    November 2022
  35. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
    Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Eur Radiol. 2022;32:7544-7554.
    PubMed     Abstract available


  36. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    PubMed     Abstract available


    October 2022
  37. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    PubMed     Abstract available


    September 2022
  38. GANDAGLIA G, Giannarini G, Stabile A, Montorsi F, et al
    Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer.
    Eur Radiol. 2022 Sep 15. pii: 10.1007/s00330-022-09096.
    PubMed    


  39. PANEBIANCO V, Turkbey B
    Magnetic resonance imaging for prostate cancer recurrence: it's time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score.
    Eur Radiol. 2022 Sep 1. pii: 10.1007/s00330-022-09095.
    PubMed    


    August 2022
  40. ROEST C, Kwee TC, Saha A, Futterer JJ, et al
    AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study.
    Eur Radiol. 2022 Aug 12. pii: 10.1007/s00330-022-09032.
    PubMed     Abstract available


  41. RUD E, Noor D, Galtung KF, Ottosson F, et al
    Validating the screening criteria for bone metastases in treatment-naive unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Eur Radiol. 2022 Aug 8. pii: 10.1007/s00330-022-08945.
    PubMed     Abstract available


    July 2022
  42. DONNERS R, Fotiadis N, Figueiredo I, Blackledge M, et al
    Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Eur Radiol. 2022 Jul 26. pii: 10.1007/s00330-022-09011.
    PubMed     Abstract available


  43. BEHESHTI M, Taimen P, Kemppainen J, Jambor I, et al
    Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Eur Radiol. 2022 Jul 21. pii: 10.1007/s00330-022-08982.
    PubMed     Abstract available


  44. HAMZAOUI D, Montagne S, Granger B, Allera A, et al
    Prostate volume prediction on MRI: tools, accuracy and variability.
    Eur Radiol. 2022;32:4931-4941.
    PubMed     Abstract available


    June 2022
  45. SUSHENTSEV N, McLean MA, Warren AY, Brodie C, et al
    The potential of hyperpolarised (13)C-MRI to target glycolytic tumour core in prostate cancer.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08929.
    PubMed     Abstract available


    May 2022
  46. TO MNN, Kwak JT
    Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08808.
    PubMed     Abstract available


    April 2022
  47. MA W, Mao J, Yang J, Wang T, et al
    Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 29. pii: 10.1007/s00330-022-08802.
    PubMed     Abstract available


  48. BLEKER J, Kwee TC, Rouw D, Roest C, et al
    A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics.
    Eur Radiol. 2022 Apr 14. pii: 10.1007/s00330-022-08712.
    PubMed     Abstract available


  49. PADHANI AR, Haider MA, Rouviere O
    Balancing the benefits and harms of MRI-directed biopsy pathways.
    Eur Radiol. 2022;32:2326-2329.
    PubMed     Abstract available


  50. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.
    Eur Radiol. 2022;32:2372-2383.
    PubMed     Abstract available


    March 2022
  51. GATTI M, Faletti R, Gentile F, Soncin E, et al
    mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging.
    Eur Radiol. 2022 Mar 15. pii: 10.1007/s00330-022-08595.
    PubMed     Abstract available


  52. ZHENG H, Miao Q, Liu Y, Mirak SA, et al
    Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
    Eur Radiol. 2022 Mar 3. pii: 10.1007/s00330-022-08625.
    PubMed     Abstract available


    February 2022
  53. PENZKOFER T, Padhani AR, Turkbey B, Ahmed HU, et al
    Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI.
    Eur Radiol. 2022 Feb 23. pii: 10.1007/s00330-022-08609.
    PubMed    


  54. DE ROOIJ M, Barentsz JO
    PI-QUAL v.1: the first step towards good-quality prostate MRI.
    Eur Radiol. 2022;32:876-878.
    PubMed     Abstract available


  55. GIGANTI F, Dinneen E, Kasivisvanathan V, Haider A, et al
    Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
    Eur Radiol. 2022;32:879-889.
    PubMed     Abstract available


    January 2022
  56. BITTENCOURT LK, Guricova K, Zucker I, Durieux JC, et al
    Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study.
    Eur Radiol. 2022 Jan 14. pii: 10.1007/s00330-021-08407.
    PubMed     Abstract available


    December 2021
  57. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.
    Eur Radiol. 2021 Dec 16. pii: 10.1007/s00330-021-08394.
    PubMed     Abstract available


    November 2021
  58. HOSSEINZADEH M, Saha A, Brand P, Slootweg I, et al
    Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.
    Eur Radiol. 2021 Nov 16. pii: 10.1007/s00330-021-08320.
    PubMed     Abstract available


  59. BOSCHHEIDGEN M, Schimmoller L, Arsov C, Ziayee F, et al
    MRI grading for the prediction of prostate cancer aggressiveness.
    Eur Radiol. 2021 Nov 8. pii: 10.1007/s00330-021-08332.
    PubMed     Abstract available


    October 2021
  60. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    PubMed     Abstract available


    September 2021
  61. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    PubMed     Abstract available


  62. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    PubMed     Abstract available


    August 2021
  63. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    PubMed     Abstract available


    July 2021
  64. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    PubMed     Abstract available


  65. BURA V, Caglic I, Snoj Z, Sushentsev N, et al
    MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
    Eur Radiol. 2021;31:4908-4917.
    PubMed     Abstract available


    May 2021
  66. PENZKOFER T, Padhani AR, Turkbey B, Haider MA, et al
    ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.
    Eur Radiol. 2021 May 15. pii: 10.1007/s00330-021-08021.
    PubMed     Abstract available


    April 2021
  67. WALLSTROM J, Geterud K, Kohestani K, Maier SE, et al
    Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial.
    Eur Radiol. 2021 Apr 23. pii: 10.1007/s00330-021-07907.
    PubMed     Abstract available


  68. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    PubMed     Abstract available


    January 2021
  69. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    PubMed     Abstract available


  70. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    PubMed     Abstract available


    November 2020
  71. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.